Luye Pharma Group (HKSE:02186) Additional Paid-In Capital : HK$4,549 Mil(As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group Additional Paid-In Capital?

Luye Pharma Group's quarterly additional paid-in capital increased from Dec. 2022 (HK$3,436 Mil) to Jun. 2023 (HK$4,037 Mil) and increased from Jun. 2023 (HK$4,037 Mil) to Dec. 2023 (HK$4,549 Mil).

Luye Pharma Group's annual additional paid-in capital increased from Dec. 2021 (HK$2,101 Mil) to Dec. 2022 (HK$3,436 Mil) and increased from Dec. 2022 (HK$3,436 Mil) to Dec. 2023 (HK$4,549 Mil).

Luye Pharma Group Additional Paid-In Capital Historical Data

The historical data trend for Luye Pharma Group's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luye Pharma Group Additional Paid-In Capital Chart

Luye Pharma Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

3,003.37

1,235.23

2,101.16

3,435.94

4,549.38

Luye Pharma Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															2,101.16	2,085.75	3,435.94	4,037.23	4,549.38

Luye Pharma Group Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Luye Pharma Group Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Luye Pharma Group's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Luye Pharma Group (HKSE:02186) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (HKSE:02186) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

LYPHF:USA LUP:Germany LUP:Germany

Address

No. 15 Chuang Ye Road, High-tech Industrial Development Zone, Shandong, Yantai, CHN, 264003

Website

https://www.luye.cn

Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on developing, producing, and selling pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for global use in Asia, Europe, and the United States.

Executives

Ubs Group Ag	2201 Interest of corporation controlled by you
Liu Dianbo	2301 Trustee
Luye Life Sciences Group Ltd	2201 Interest of corporation controlled by you
Luye Pharma Holdings Ltd.	2201 Interest of corporation controlled by you
Nelumbo Investments Limited	2201 Interest of corporation controlled by you
Shorea Lbg	2201 Interest of corporation controlled by you
Luye Pharmaceutical Investment Co., Ltd.	2101 Beneficial owner
Ginkgo (ptc) Limited	2301 Trustee
Luye Pharmaceutical International Co., Ltd.	2201 Interest of corporation controlled by you
Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Hillhouse Nev Holdings Limited	2101 Beneficial owner
Hillhouse Investment Management, Ltd.	2102 Investment manager
Hillhouse Fund V, L.p.	2201 Interest of corporation controlled by you
Xin Ye Sheng Wu Yi Yao Kong Gu You Xian Gong Si
Yang Yu Fen

Luye Pharma Group (HKSE:02186) Headlines

No Headlines